The Gut Endocannabinoid System
The gastrointestinal tract is densely populated with cannabinoid receptors. CB1 receptors sit on enteric neurons (the gut’s “second brain”), regulating motility, secretion, and visceral pain. CB2 receptors are concentrated on immune cells throughout the gut, regulating inflammation. Endocannabinoids (anandamide and 2-AG) are produced locally and modulate gut function continuously.
This dense receptor distribution gives cannabinoids a plausible mechanism for affecting gut symptoms across multiple disorders — from IBS (a functional disorder without visible inflammation) to Crohn’s and ulcerative colitis (chronic inflammatory diseases with structural damage).
Irritable Bowel Syndrome (IBS)
IBS affects ~10–15% of adults, with prevalence rising in older populations. Symptoms: abdominal pain, bloating, altered bowel habits (diarrhea-predominant, constipation-predominant, or mixed). No structural damage; standard treatments target individual symptoms.
Cannabis evidence
The endocannabinoid deficiency hypothesis (Russo 2004, refined since) proposes that IBS, fibromyalgia, and migraine share an underlying deficit in endocannabinoid signaling. The hypothesis is plausible and has driven interest in cannabis for IBS, but large definitive RCTs are missing.
Observational data suggests benefit for pain, nausea, and gut hypermotility in IBS-D (diarrhea-predominant) patients. CB1 activation reduces gut motility — useful for IBS-D, potentially counterproductive for IBS-C (constipation-predominant). THC’s antiemetic effect helps with the nausea component.
Practical approach for older adults with IBS
- For IBS-D: low-dose THC sublingual (2.5–5 mg) before meals or at the onset of symptoms. CBD-dominant tincture for ongoing visceral hypersensitivity.
- For IBS-C: avoid daily THC (slows motility, can worsen constipation). CBD-only products may be better.
- For IBS-mixed: dose situationally rather than scheduled.
Crohn’s Disease
Crohn’s is a chronic inflammatory disease that can affect any part of the GI tract from mouth to anus. Symptoms include abdominal pain, diarrhea, fatigue, weight loss, and complications including fistulas and strictures.
Cannabis evidence
Two small Israeli RCTs from the Naftali group are the most-cited:
- Naftali 2013 — smoked cannabis vs. placebo in 21 Crohn’s patients refractory to standard therapy. Significant improvement in Crohn’s Disease Activity Index (CDAI) scores in 90% of cannabis-treated patients vs. 40% of controls. However: CDAI is symptom-based; objective inflammatory markers (CRP) did not improve.
- Naftali 2017 — CBD-only oil in 20 Crohn’s patients; no significant improvement vs. placebo.
The pattern: cannabis appears to improve subjective symptoms and quality of life in Crohn’s without clearly improving the underlying inflammation. This is consistent with cannabis as symptom management, not disease modification. Your biologic (infliximab, adalimumab, ustekinumab, vedolizumab) is what addresses the inflammation; cannabis can help you feel better while your biologic does its work.
Ulcerative Colitis
Similar pattern to Crohn’s. The Naftali group also studied UC; signal of symptom improvement without clear inflammatory benefit. Standard UC therapies (5-ASA agents, biologics, JAK inhibitors) remain the foundation; cannabis is adjunctive.
Practical Considerations for Older Adults
Drug interactions
IBD and IBS patients are commonly on:
- Biologics (anti-TNF, anti-integrin, anti-IL agents) — no direct cannabis interaction; cannabis can compound immunosuppression in theory but limited clinical concern.
- Corticosteroids (prednisone, budesonide) — no direct interaction; both can cause sleep disturbance.
- Tricyclic antidepressants (used for IBS visceral pain) — additive anticholinergic effects with cannabis.
- Loperamide and other antidiarrheals — for IBS-D; cannabis may compound the motility-slowing effect.
- Antispasmodics (dicyclomine, hyoscyamine) — additive anticholinergic effects with cannabis (dry mouth, constipation, confusion).
See Cannabis Drug Interactions.
Forms
Sublingual tincture is the easiest form for predictable dose control. Edibles produce a longer-lasting effect appropriate for chronic gut symptoms but the slow onset (60–120 min) makes acute symptom management awkward. Vaporized cannabis works fastest for acute breakthrough symptoms. Suppositories can deliver cannabinoids regionally to lower GI/colonic tissue (limited availability commercially).
Cannabinoid hyperemesis syndrome (CHS) caution
Heavy long-term cannabis users can develop CHS — a paradoxical syndrome of cyclical vomiting, abdominal pain, and compulsive hot showers. The clinical picture overlaps confusingly with active Crohn’s flare or severe IBS exacerbation. If you’re using cannabis daily for IBD/IBS and your symptoms paradoxically worsen, consider CHS in the differential. The only treatment is cannabis cessation.
Realistic Expectations
Cannabis for inflammatory bowel conditions is best framed as symptom relief and quality-of-life improvement, not disease modification. Patients commonly report meaningful benefit in pain, sleep, appetite, and overall well-being. Inflammatory markers (CRP, fecal calprotectin) typically don’t change. Continue your gastroenterologist-prescribed regimen; cannabis is an addition, not a replacement.
Bottom Line
The gut endocannabinoid system is dense, and cannabinoids have plausible mechanisms in IBS, Crohn’s, and UC. Clinical evidence supports symptom improvement (pain, nausea, appetite, quality of life) more clearly than it supports inflammation reduction. For older adults, sublingual tinctures with predictable dosing are the easiest starting point; coordinate with your gastroenterologist about interactions with biologics, antidepressants used for IBS, and antispasmodics. Watch for cannabinoid hyperemesis syndrome if symptoms paradoxically worsen with daily use.